Barclays analyst John Babcock has maintained an Underweight rating on Copart (NASDAQ: CPRT) and lowered the price target to $26 from $32. The revision signals a more cautious stance on the company's near-term stock performance potential.

Rating and Price Target Details

The decision to lower the price target follows a review of Copart's current market position and future prospects. The new target of $26 represents a decrease from the previous estimate of $32.

The Underweight rating suggests that the analyst expects the stock to underperform relative to the broader market or its sector peers in the coming period.

Bragar Eagel & Squire, P.C. is investigating potential claims against Copart, Inc. on behalf of stockholders regarding possible violations of federal securities laws. The investigation scrutinizes whether the company engaged in unlawful business practices. Investors who purchased Copart securities and suffered losses are encouraged to contact partners Brandon Walker or Melissa Fortunato to discuss their legal rights.

The legal action follows a significant leadership transition announced on June 29, 2026. Copart disclosed that Jeff Liaw would step down from his roles as Chief Executive Officer and member of the board of directors, effective July 31, 2026. This announcement triggered an immediate negative market reaction.

Following the news, Copart's stock price declined sharply. The shares fell $2.45, a drop of 8.02%, to close at $28.10 per share on June 29, 2026. This decline represents a material loss in market value for shareholders on the day of the announcement.

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation. Investors can reach the firm by telephone at (212) 355-4648 or via email at investigations@bespc.com .

Key Details